Overcoming antigen loss in CAR T therapy with Vγ9Vδ2 CAR T-cells
Vγ9Vδ2 CAR T-cell therapy presents a promising strategy for B-cell malignancies, offering sustained antitumor activity even after antigen loss. This approach may help overcome a major limitation of conventional CAR T-cell therapy, potentially improving clinical outcomes.
Authors
- Pia Aehnlich (ORCID: https://orcid.org/0000-0001-6758-001X)
- Per thor Straten (ORCID: https://orcid.org/0000-0002-4731-4969)
- Thomas Morgan Hulen (ORCID: https://orcid.org/0000-0003-2475-6526)
- Özcan Met (ORCID: https://orcid.org/0000-0002-3256-7592)
- Marta Velasco Santiago (ORCID: https://orcid.org/0000-0002-3322-3513)
- Klaus Møller‐Ernst Jensen
- Gerd Olofsson
Institutions
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Technical University of Denmark (DK)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.iotech.2025.101053
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research Institute
- Dagmar Marshalls Fond
- Aase og Ejnar Danielsens Fond
- Danmarks Frie Forskningsfond
- Familien Erichsens Mindefond
- KV Fonden